Market Research Logo

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H1 2018

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H1 2018

Summary

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent.

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline Target constitutes close to 28 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 9, 3, 11 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Immunology, Oncology, Hematological Disorders, Dermatology, Gastrointestinal, Ophthalmology, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Rheumatoid Arthritis, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Waldenstrom Macroglobulinemia, Autoimmune Disorders, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Peripheral T-Cell Lymphomas (PTCL), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Allergic Conjunctivitis, Asthma, Atopic Dermatitis, B-Cell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Marginal Zone B-cell Lymphoma, Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Ulcerative Colitis, Acquired (Autoimmune) Hemolytic Anemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Allergies, Alzheimer's Disease, Anaphylactic Shock, Arthritis, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Blood Cancer, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Urticaria Or Hives, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glomerulonephritis, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Inflammation, Inflammatory Bowel Disease, Keratoconjunctivitis sicca (Dry Eye), Kidney Transplant Rejection, Lupus Nephritis, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Myelofibrosis, Non-Small Cell Lung Cancer, Peritoneal Cancer, Post-Transplant Lymphoproliferative Disorder, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sicca Syndrome (Sjogren), Solid Tumor, Subacute Cutaneous Lupus Erythematosus (SCLE) and Systemic Lupus Erythematosus.

The latest report Tyrosine Protein Kinase SYK - Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
AB Science SA
Almirall SA
Archer Pharmaceuticals Inc
Asana BioSciences LLC
Beijing Hanmi Pharmaceutical Co Ltd
Celgene Corp
Clevexel Pharma SAS
Fujifilm Holdings Corporation
Genosco Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Hutchison MediPharma Ltd
Japan Tobacco Inc
Levolta Pharmaceuticals Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Portola Pharmaceuticals Inc
Rigel Pharmaceuticals Inc
Taiho Pharmaceutical Co Ltd
TopiVert Ltd
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Drug Profiles
AB-8779 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-509 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cerdulatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVXL-0074 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entospletinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FF-10102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fostamatinib disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-492429 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-9876 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2646264 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMPL-523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTE-852 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAS-189386 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nilvadipine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRT-2761 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKIO-703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SYK and JAK for Autoimmune Disorders and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SYK for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-659 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-05567 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1630 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOP-1890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Product Development Milestones
Featured News & Press Releases
Apr 30, 2018: TAVALISSE (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo
Apr 25, 2018: Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 17, 2018: Rigel Announces FDA Approval of TAVALISSE (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Apr 12, 2018: Rigel Makes Statement Regarding Website Error
Apr 03, 2018: Rigel Announces Top line Data From Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy
Mar 01, 2018: Rigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America
Jan 08, 2018: TopiVert announces positive results from the Phase 1 study with its oral formulation of TOP1288 for the treatment of ulcerative colitis
Jan 04, 2018: Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference
Jan 04, 2018: Asana BioSciences Announces Achievement of Positive Results in the Clinical Proof of Concept Study in Atopic Dermatitis with ASN002, A Novel Oral JAK/SYK Inhibitor
Dec 08, 2017: Rigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting
Nov 30, 2017: Portola Pharmaceuticals to Present New Data on Cerdulatinib at the 59th American Society of Hematology (ASH) Annual Meeting
Nov 28, 2017: TopiVert Demonstrates Proof Of Concept In Phase 1/2a Study of TOP1630 in Treatment Of Dry Eye Syndrome
Nov 01, 2017: Takeda to Present Data On TAK-659 During 59th ASH Annual Meeting
Oct 03, 2017: Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia Phase 2 Study
Oct 02, 2017: Rigel Provides Update on FDA Review of Fostamatinib for ITP
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AB Science SA, H1 2018
Pipeline by Almirall SA, H1 2018
Pipeline by Archer Pharmaceuticals Inc, H1 2018
Pipeline by Asana BioSciences LLC, H1 2018
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2018
Pipeline by Celgene Corp, H1 2018
Pipeline by Clevexel Pharma SAS, H1 2018
Pipeline by Fujifilm Holdings Corporation, H1 2018
Pipeline by Genosco Inc, H1 2018
Pipeline by Gilead Sciences Inc, H1 2018
Pipeline by GlaxoSmithKline Plc, H1 2018
Pipeline by Hutchison MediPharma Ltd, H1 2018
Pipeline by Japan Tobacco Inc, H1 2018
Pipeline by Levolta Pharmaceuticals Inc, H1 2018
Pipeline by Merck KGaA, H1 2018
Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Pipeline by Portola Pharmaceuticals Inc, H1 2018
Pipeline by Rigel Pharmaceuticals Inc, H1 2018
Pipeline by Taiho Pharmaceutical Co Ltd, H1 2018
Pipeline by TopiVert Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Dormant Products, H1 2018 (Contd..2), H1 2018
Discontinued Products, H1 2018
List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report